In clinical cases, it has been reported that serum Trx levels are increased in patients with NASH by comparison to healthy controls, indicating that Trx may elicit a hepatoprotective function by increasing its expression during hepatic injury [17]. This evidence concerns the gene TXN and metabolic dysfunction-associated steatohepatitis.